Mirum Pharmaceuticals, Inc.

At its core, Mirum Pharma is a business development success story. CEO Chris Peetz sat down with In Vivo to discuss Mirum’s commercial momentum, near-term catalysts and the company’s vision for beco

The disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan